Moderna and Merck Vaccine Blocks Melanoma Return

A new vaccine developed by Moderna and Merck has shown promising results in preventing the return of melanoma, according to a recent trial.

The Food and Drug Administration-approved mRNA therapy was tested on patients with a history of melanoma, and it successfully blocked the cancer's return.

The researchers are optimistic that these personalized treatments could be effective against other cancers as well.